FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2301024097> ?p ?o ?g. }

• W2301024097 endingPage "1000" @default.
• W2301024097 startingPage "1000" @default.
• W2301024097 abstract "Abstract Introduction Hydroxyurea (HU) therapy ameliorates the morbidity associated with Sickle cell anemia (SCA). HU is typically escalated to maximum tolerated doses (MTD) for treatment of SCA patients. Monitoring HU for toxicity poses potential challenges in low resource settings. We have previously reported the safety and efficacy of fixed low dose HU at 10mg/kg body weight ( Jain et al 2013). We studied the long term safety and efficacy of low dose HU in pediatric patients with SCA. Methods Long term observational follow up of 40 young Indian SCA patients was carried out for a period of 10 years in a single tertiary care center in central India. The number of clinical events including vasocclusive crises, acute chest syndrome, stroke, sequestration crises, avascular bone necrosis in the entire cohort was assessed prior to starting HU and subsequently every 3 months. Laboratory parameters including hemoglobin levels, Hb F levels, mean corpuscular volume, mean corpuscular hemoglobin concentration were also followed up over the same time period. Results The total number of patients in this study was 40 (17 females & 23 males). Mean age was 12.95 years ± 9.62. All patients had HbSS. There was an increase in mean hemoglobin, HbF, MCV and MCH over time in the patient population ( Table 1). There was a decrease in the mean number of hospitalizations, vasocclusive crises, acute chest syndromes, stroke and severe anemia ( Table 2). HU was well tolerated with minimal hematological or other toxicity (Table3). Patients who experienced transient hematological, liver or renal toxicity were able to resume HU at the same dose. HU was permanently discontinued in 2 patients who had manifestations of HIV/AIDS. HU was temporarily interrupted in one patient who was receiving treatment for tuberculosis and in one patient for the duration of a normal pregnancy. There was one death attributable to severe septicemia without evidence of neutropenia after 2 years follow up. There were 3 subjects who were lost to follow up, one after 2 years follow up and remaining 2 after 5 years of follow up. Of note, patients had a high HbF level at baseline. High HbF levels at baseline, the variable relationship of HbF to disease severity and amelioration of disease in Indian patients with high HbF has been previously reported ( Jain et al 2012, Patel et al 2012, Italia et al 2009). Conclusions Low fixed dose HU is well tolerated and is efficacious in reducing incidence of VOC, hospitalizations, severe anemia, stroke and acute chest syndrome. Low fixed dose HU may be advantageous in low resource settings because of lower toxicity and consequently less need for monitoring. There is a need for multi-center randomized comparisons of low fixed dose HU with conventional escalation of HU dose to MTD. Disclosures: Krishnamurti: GlycoMimetics, Inc.: Research Funding." @default.
• W2301024097 created "2016-06-24" @default.
• W2301024097 creator A5016940162 @default.
• W2301024097 creator A5032922332 @default.
• W2301024097 creator A5072101808 @default.
• W2301024097 creator A5073529037 @default.
• W2301024097 creator A5077361121 @default.
• W2301024097 date "2013-11-15" @default.
• W2301024097 modified "2023-10-14" @default.
• W2301024097 title "Long Term Safety and Efficacy Of Low Fixed Dose Hydroxyurea In Pediatric Patients With Sickle Cell Anemia: A Single Center Study From Central India" @default.
• W2301024097 doi "https://doi.org/10.1182/blood.v122.21.1000.1000" @default.
• W2301024097 hasPublicationYear "2013" @default.
• W2301024097 type Work @default.
• W2301024097 sameAs 2301024097 @default.
• W2301024097 citedByCount "3" @default.
• W2301024097 countsByYear W23010240972018 @default.
• W2301024097 countsByYear W23010240972021 @default.
• W2301024097 countsByYear W23010240972022 @default.
• W2301024097 crossrefType "journal-article" @default.
• W2301024097 hasAuthorship W2301024097A5016940162 @default.
• W2301024097 hasAuthorship W2301024097A5032922332 @default.
• W2301024097 hasAuthorship W2301024097A5072101808 @default.
• W2301024097 hasAuthorship W2301024097A5073529037 @default.
• W2301024097 hasAuthorship W2301024097A5077361121 @default.
• W2301024097 hasConcept C126322002 @default.
• W2301024097 hasConcept C141071460 @default.
• W2301024097 hasConcept C172680121 @default.
• W2301024097 hasConcept C187212893 @default.
• W2301024097 hasConcept C2776317666 @default.
• W2301024097 hasConcept C2778248108 @default.
• W2301024097 hasConcept C2778620579 @default.
• W2301024097 hasConcept C2778917026 @default.
• W2301024097 hasConcept C2779134260 @default.
• W2301024097 hasConcept C2779234561 @default.
• W2301024097 hasConcept C2780073493 @default.
• W2301024097 hasConcept C2780554921 @default.
• W2301024097 hasConcept C2780976302 @default.
• W2301024097 hasConcept C2781058662 @default.
• W2301024097 hasConcept C2908647359 @default.
• W2301024097 hasConcept C54355233 @default.
• W2301024097 hasConcept C71924100 @default.
• W2301024097 hasConcept C72563966 @default.
• W2301024097 hasConcept C86803240 @default.
• W2301024097 hasConcept C90924648 @default.
• W2301024097 hasConcept C99454951 @default.
• W2301024097 hasConceptScore W2301024097C126322002 @default.
• W2301024097 hasConceptScore W2301024097C141071460 @default.
• W2301024097 hasConceptScore W2301024097C172680121 @default.
• W2301024097 hasConceptScore W2301024097C187212893 @default.
• W2301024097 hasConceptScore W2301024097C2776317666 @default.
• W2301024097 hasConceptScore W2301024097C2778248108 @default.
• W2301024097 hasConceptScore W2301024097C2778620579 @default.
• W2301024097 hasConceptScore W2301024097C2778917026 @default.
• W2301024097 hasConceptScore W2301024097C2779134260 @default.
• W2301024097 hasConceptScore W2301024097C2779234561 @default.
• W2301024097 hasConceptScore W2301024097C2780073493 @default.
• W2301024097 hasConceptScore W2301024097C2780554921 @default.
• W2301024097 hasConceptScore W2301024097C2780976302 @default.
• W2301024097 hasConceptScore W2301024097C2781058662 @default.
• W2301024097 hasConceptScore W2301024097C2908647359 @default.
• W2301024097 hasConceptScore W2301024097C54355233 @default.
• W2301024097 hasConceptScore W2301024097C71924100 @default.
• W2301024097 hasConceptScore W2301024097C72563966 @default.
• W2301024097 hasConceptScore W2301024097C86803240 @default.
• W2301024097 hasConceptScore W2301024097C90924648 @default.
• W2301024097 hasConceptScore W2301024097C99454951 @default.
• W2301024097 hasIssue "21" @default.
• W2301024097 hasLocation W23010240971 @default.
• W2301024097 hasOpenAccess W2301024097 @default.
• W2301024097 hasPrimaryLocation W23010240971 @default.
• W2301024097 hasRelatedWork W2034966366 @default.
• W2301024097 hasRelatedWork W2123630932 @default.
• W2301024097 hasRelatedWork W2195280390 @default.
• W2301024097 hasRelatedWork W2319862760 @default.
• W2301024097 hasRelatedWork W2320291581 @default.
• W2301024097 hasRelatedWork W2333538367 @default.
• W2301024097 hasRelatedWork W2352805165 @default.
• W2301024097 hasRelatedWork W2386022156 @default.
• W2301024097 hasRelatedWork W2578100537 @default.
• W2301024097 hasRelatedWork W4231348632 @default.
• W2301024097 hasVolume "122" @default.
• W2301024097 isParatext "false" @default.
• W2301024097 isRetracted "false" @default.
• W2301024097 magId "2301024097" @default.
• W2301024097 workType "article" @default.